ACUT.US Accustem Sciences Inc

Healthcare Biotechnology USA Stocks
0.1300 USD
Close of Nov 13, 2026
0.1170 0.9979
Market cap
USD 2.09M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ACUT.US undervalued?

Graham number

The Graham number of Accustem Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Accustem Sciences Inc fundamental analysis

No fundamental analysis for Accustem Sciences Inc yet.

Accustem Sciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Accustem Sciences Inc

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuSt…

Full company profile